clinical trial · NCT06029309
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Alvaro Alencar, MD·phase2·recruiting·n = 27
Mantle Cell LymphomaZanubrutinibTafasitamab
brief summary
The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.
started
May 3, 2024
primary completion
May 1, 2028
completion
May 1, 2032
last updated
Oct 6, 2025
official title
A Phase 1/2 Study of Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol